IDEAS Study: Closing in on a Terrible Killer

Barry Siegel.jpg

The IDEAS Study site map appears on the monitor behind Dr. Siegel

This post was contributed by Barry A. Siegel, MD, professor of radiology at Washington University School of Medicine, IDEAS Study co-investigator, and previously co-chair of the National Oncologic PET Registry (NOPR).

IDEAS Study results published this week in JAMA confirm that amyloid PET imaging serves a vital role in the management and diagnosis of the 5.5 million Americans suffering with Alzheimer’s – the nation’s sixth leading cause of death.

PET imaging used to detect Alzheimer’s-related plaques in the brain changed management of nearly two-thirds of patients with mild cognitive impairment and dementia – and diagnosis of the cause of these effects in nearly a third of such patients.

What’s more, the study results are generalizable across much of the US population as participating sites included community clinics, freestanding imaging centers and other non-academic settings – in addition to large teaching hospitals.

At present, there is no cure for Alzheimer’s disease – but research is actively ongoing on many fronts.

I am proud that the American College of Radiology managed this landmark trial and that radiologists are such a large part of this great effort.

Please share your thoughts in the comments section below and join the discussion on Engage (login required).